Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) shot up 2.9% on Wednesday . The company traded as high as $4.99 and last traded at $4.92, with a volume of 177,163 shares trading hands. The stock had previously closed at $4.78.

A number of brokerages have weighed in on ARGS. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Monday, August 15th. FBR & Co lowered their price target on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Argos Therapeutics in a research report on Friday, June 17th. Eight investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $11.50.

The firm’s market cap is $203.92 million. The company has a 50 day moving average of $5.19 and a 200 day moving average of $5.91.

Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, equities analysts expect that Argos Therapeutics Inc. will post ($1.49) EPS for the current fiscal year.

In other news, major shareholder International S. Pharmstandard purchased 75,474 shares of the company’s stock in a transaction that occurred on Monday, August 22nd. The stock was acquired at an average cost of $4.24 per share, with a total value of $320,009.76. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder International S. Pharmstandard purchased 67,371 shares of the company’s stock in a transaction that occurred on Wednesday, August 24th. The shares were purchased at an average cost of $4.52 per share, with a total value of $304,516.92. The disclosure for this purchase can be found here.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.